Combination therapy for HIV: towards long term control of disease progression

Bibliography

• PERELSON AS, NEUMANN AU, MARKOWITZ M, LEONARD JM, HO DD: 11IV-1 dynamics in viva virion clearance rate, infected cell lifespan and viral generation time. Science (1996) 271:1582–1586.
   PubMed Web of Science ®Google Scholar
• ••The landmark paper in this field, defining all the concepts inuse today.
   Google Scholar
• O'BRIEN WA, HARTIGAN PM, MARTIN D et al.: Changes in 11IV-1 RNA and CD4 lymphocyte counts and the risk of progression to AIDS. New Engl. J. Med. (1996) 334:426–431.
   Google Scholar
• HAMMER SM, KATZENSTEIN DA, HUGHES MD et al.: Atrial comparing nucleoside monotherapy with combi-nation therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimetre. AIDS Clinical Trials Group Study 175 Study Team. New Engl. J. Med. (1996) 335:1081–1090.
   Google Scholar
• KATZENSTEIN DA, HAMMER SM, HUGHES MD et al: Therelation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic mil-limetre. AIDS Clinical Trials Group Study 175 Virology Study Team. New Engl. J. Med. (1996) 335:1091–1098.
   PubMed Web of Science ®Google Scholar
• DELTA CO-ORDINATING COMMITTEE: A randomised double-blind controlled trial comparing combina-tions of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet (1996) 348:283–291.
   PubMed Web of Science ®Google Scholar
• GULICK RM, MELLORS JW, HAVLIR D et al.: Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Engl. J. Med. (1997) 337:734–739.
   PubMed Web of Science ®Google Scholar
• MONTANER JSG, REISS P, COOPER D et al: A random- ised, double-blinded trial comparing the immunologic and virologic effects of nevirapine, didanosine and zi-dovudine combinations among antiretroviral naive, AIDS-free, 11IV-1 infected gatients with CD4 counts be-tween 200 and 600/mm . J. Am. Med. Assoc. (1998) 279:930–937.
   Web of Science ®Google Scholar
• ••The first large-scale demonstration of the efficacy ofnevirapine-containing regimens in drug-naive patients.
   Google Scholar
• RABOUD JM, MONTANER JSG, RAE S et al.: Predictors of duration of plasma viral load suppression. 37th In-terscience Conference on Antimicrobial Agents and Chemo-therapy. Toronto, Canada (1997). Abstract A14.
   Google Scholar
• DEMASI R, HILL A, DAWSON D: Meta-analysis of the con-cordance between anti-retroviral effects on 11IV-1 RNA and CD4 count and progression to AIDS or death. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1998). Abstract 220.
   Google Scholar
• CARPENTER CCJ, FISCHL MA, HAMMER SM et al: Antiret-roviral therapy for HIV infection in 1997. J. Amer. Med. Assoc. (1997) 277:1962–1969.
   Google Scholar
• ••The standard of care in the USA, updated yearly.
   Google Scholar
• PERELSON AS, ESSUNGER P, CAO Y et al.: Decay charac-teristics of 11IV-1-infected compartments during com-bination therapy. Nature (1997) 387:188–191.
   PubMed Web of Science ®Google Scholar
• WONG JK, HEZAREH M, NTHARD HFG et al: Recovery of replication-competent HIV despite prolonged sup-pression of plasma viremia. Science (1997) 278:1291–1295.
   PubMed Web of Science ®Google Scholar
• ••The formal demonstration of the limitations of current an-tiretroviral therapy regimens.
   Google Scholar
• FINZI D, HERMANKOVA M, PIERSON T et al.: Identifica- tion of a reservoir for 11IV-1 in patients on highly ac-tive antiretroviral therapy. Science (1 9 9 7) 278:1295-1300.
   Google Scholar
• ••Companion article to [12].
   Google Scholar
• RUTSCHMANN 0, HIRSCHEL B: Antiretroviral therapy: a guide to the most important trials. Schweiz. Med. Wo-chenschr. (1997) 127:436–443.
   PubMed Web of Science ®Google Scholar
• STASZEWSKI S, HILL AM, BARTLETT J et al.: Reductions in11IV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of con-trolled trials. AIDS (1997) 11:477–483.
   PubMed Web of Science ®Google Scholar
• SPRUANCE SL, PAVIA AT, MELLORS JW et al.: Clinical effi-cacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomised, double-blind controlled trial. Bristol-Myers Squibb Stavudine/019 Study group. Ann. Intern. Med. (1997) 126:355–363.
   Google Scholar
• BALFOUR HH, ERICE A, REED NV, ALLMAN AR, LI W: Therapy with d4T plus 3TC produces sustained unde-tectable levels of plasma HIV RNA (pHIV) in patients treated with reverse transcriptase (RT) inhibitors for 10 years. 5th Conference on Retro viruses and Opportunistic Infections. Chicago, USA (1998). Abstract 664.
   Google Scholar
• ROULEAU D, CONWAY B, RABOUD J et al.: Stavudineplus lamivudine in advanced human immunodefi-ciency virus disease: a short-term pilot study. J. Infect. Dis. (1997) 176:1156–1160.
   PubMedGoogle Scholar
• KURITZKES DR, MARSCHNER IC, JOHNSON VA et al.: A randomised, double-blind, placebo-controlled trial of lamivudine (3TC) in combination with zidovudine (ZDV), stavudine (d4T), or didanosine (ddl) in treat-ment naive patients. 5th Conference on Retro viruses and Opportunistic Infections. Chicago, USA (1998). Abstract 1.
   Google Scholar
• SOMMADOSSI JP, ZHOU XJ, MOORE J et al.: Impairment of Stavudine (d4T) phosphorylation in patients receiv-ing a combination of zidovudine (ZDV) and d4T (ACTG 290). 5th Conference on Retro viruses and Opportunistic In-fections. Chicago, USA (1998). Abstract 3.
   Google Scholar
• ••An essential concept, which may revolutionise our use ofnucleoside analogue combinations.
   Google Scholar
• O'SHAUGHNESSY MV, HOGG RS, RHONE SA et al: Do dual nucleoside regimens have a role in an era of plasma viral load driven antiretroviral therapy? 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1998). Abstract 668.
   Google Scholar